According to Hisco, recently, the innovative drug HSK42360-na tablets independently developed by Hisco were officially included in the “List of Breakthrough Therapeutics” by the Drug Evaluation Center of the State Drug Administration. After HSK42360-na tablets are included in breakthrough treatments, they will greatly promote the development process of new drugs in this field. It is expected that they will obtain priority review qualifications during the marketing application stage, accelerate marketing, and bring new hope for the treatment of glioma patients.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.